NDA 016151 · Quagen
Urex
Methenamine Hippurate · Oral
Last checked: Nov 19, 2026Latest source record: Mar 30, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1967
Jul 5, 1967
Approved uses
1
Original approval plus efficacy supplements
Registered trials
11
0 Phase 3, 2 recruiting
FAERS reports
1,289
736 serious, 82 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 17, 2024.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Methenamine Hippurate Tablets and other antibacterial drugs, Methenamine Hippurate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Methenamine Hippurate Tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 5, 1967 Original approval · Type 2 - New Active Ingredient
1 products under this application
- UREX · METHENAMINE HIPPURATE 1GM · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Methenamine Hippurate" as an intervention, any sponsor and status, largest first.
- The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTIPivotal-lookingCompleted
University of OsloAcademic, hospital or other
NCT04077580 · 289 participants · Start Nov 1, 2019 · Primary completion Jun 30, 2023
Drug: Methenamine Hippurate 1000 MG · For: Recurrent Urinary Tract Infection
Sites: Utrecht, Netherlands; Oslo, Norway; Lodz, Poland · 4 sites in all
- Short-course Methenamine Hippurate for Prevention of Post-operative UTIPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT02358993 · 201 participants · Start Dec 2014 · Primary completion Sep 30, 2020
Drug: methenamine hippurate; Ciprofloxacin · For: Urinary Tract Infections; Catheter-Related Infections
Sites: Philadelphia, Pennsylvania · 4 sites in all
University College, LondonAcademic, hospital or other
NCT07202949 · 192 participants (planned) · Start Feb 26, 2026 · Primary completion Oct 2027
Drug: Treatment dose antibiotic in combination with methenamine hippurate; Prophylactic dose antibiotic or methenamine hippurate monotherapy · For: Chronic Urinary Tract Infection
Sites: Yorkshire, United Kingdom; London, United Kingdom; Manchester, United Kingdom · 5 sites in all
- Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?Pivotal-lookingActive, not recruiting
Atlantic Health SystemAcademic, hospital or other
NCT06810687 · 190 participants (planned) · Start Jan 30, 2025 · Primary completion Jul 30, 2027
Drug: Methenamine Hippurate 1g BD · For: Urinary Tract Infection (Diagnosis)
Sites: Morristown, New Jersey
- Urinary Track Infection Prevention After Urogynecological SurgeryPivotal-lookingCompleted
TriHealth Inc.Academic, hospital or other
NCT03818321 · 185 participants · Start Jun 17, 2019 · Primary completion Jul 1, 2021
Drug: Methenamine Hippurate 1 g tablet; Placebo tablet · For: Urinary Tract Infections; Urinary Retention Postoperative; Pelvic Organ Prolapse
Sites: Cincinnati, Ohio
- Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA InjectionPivotal-lookingRecruiting
Women and Infants Hospital of Rhode IslandAcademic, hospital or other
NCT06953271 · 164 participants (planned) · Start Aug 1, 2025 · Primary completion Jan 30, 2027
Drug: Methenamine Hippurate; Typically prescribed oral antibiotic prophylaxis · For: Overactive Bladder (OAB); Urinary Tract Infection (Diagnosis)
Sites: Providence, Rhode Island
Endeavor HealthAcademic, hospital or other
NCT03077711 · 92 participants · Start Jun 2016 · Primary completion Jun 21, 2019
Drug: Trimethoprim; Methenamine hippurate · For: Urinary Tract Infections, Recurrent
Sites: Skokie, Illinois
- Vitamin C and Hiprex in rUTINot yet recruiting
University Hospitals of North Midlands NHS TrustAcademic, hospital or other
NCT06710899 · 20 participants (planned) · Start Jan 2027 · Primary completion Aug 2027
Drug: Methenamine Hippurate 1g BD; Methenamine Hippurate 1g BD + Vitamin C 1g BD · For: Urinary Tract Infections
Sites: Stoke-on-Trent, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urinary tract infection169
- diarrhoea83
- drug ineffective83
- nausea83
- fatigue78
- fall74
- headache70
- dizziness66
- death57
- product dose omission issue57
- off label use52
- pneumonia51
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 10 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 13 |
| 2013 | 9 |
| 2014 | 25 |
| 2015 | 52 |
| 2016 | 65 |
| 2017 | 58 |
| 2018 | 67 |
| 2019 | 72 |
| 2020 | 92 |
| 2021 | 91 |
| 2022 | 97 |
| 2023 | 115 |
| 2024 | 129 |
| 2025 | 180 |
| 2026 | 200 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness of methenamine hippurate in preventing urinary tract infections: an updated systematic review, meta-analysis and trial sequential analysis of randomized controlled trials.
Hobaica NC, De Oliveira GC, Porto BC, et al. · BMC Urol 2025 · Systematic Review, Meta-Analysis
- Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial.
Harding C, Mossop H, Homer T, et al. · BMJ 2022 · Equivalence Trial, Multicenter Study
- Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women-a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU).
Heltveit-Olsen SR, Arnljots ES, Sundvall PD, et al. · Clin Microbiol Infect 2025 · Randomized Controlled Trial, Clinical Trial, Phase IV
- Methenamine hippurate (Hiprex).
· Med Lett Drugs Ther 1968 · Clinical Trial
- The resurgence of methenamine hippurate in the prevention of recurrent UTIs in women- a systematic review.
Kale S, Somani BK · Curr Opin Urol 2023 · Systematic Review
- Probiotics for preventing urinary tract infection in people with neuropathic bladder.
Toh SL, Boswell-Ruys CL, Lee BSB, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Quagen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.